Skip to main content
SpringerLink
Log in

Surfactant Therapy

  • Chapter
  • First Online:
Pediatric Critical Care Medicine

  • 2733 Accesses

Abstract

Pulmonary surfactant is the evolutionary solution to the problem of surface tension and air breathing. Without surfactant, each breath would require inordinate energy expenditure to expose the huge intrapulmonary surface to inspired air, and life on land, at least as we know it, would be virtually impossible. Pulmonary surfactant exists in the alveolar hypophase in a complex microstructure of phospholipid-rich aggregates with incorporated four distinct surfactant proteins, each with their own function. Pulmonary surfactant serves two primary functions in the lungs. It is first and foremost a surface-active agent that lowers and varies surface tension to reduce the work of breathing, stabilize alveoli against collapse and over-distension, and lessen the hydrostatic driving force for edema fluid to transudate into the interstitium and alveoli. In addition, the specific apoprotein components of lung surfactant have been found to play an important role in the lung’s innate immune response.

The crucial physiological importance of lung surfactant in respiration is demonstrated by the fact that a lack of this material in premature infants contributes to the development neonatal respiratory distress syndrome, a potentially fatal disease process. Exogenous surfactant replacement is now standard of care in the treatment of premature infants, and can be argued as being the most important discovery in pediatric medicine in the past 30 years. Despite this breakthrough in the treatment of neonatal lung disease, it is clear that the pathophysiology of acute pulmonary injury outside of the neonatal period is much different, and multifactorial, including inflammation, surfactant dysfunction, vascular dysfunction, edema, oxidant injury, ventilation/perfusion mismatching, and injury to alveolar, capillary, and other pulmonary cells. Clinical studies of multiple surfactant preparations in multiple target populations have resulted in unequivocal results. Therefore, the use of exogenous surfactants for the treatment of acute lung disease outside of the neonatal period is much more uncertain and complex, and remains the subject of on-going research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. von Neergaard K. Neue auffassungen uber einen grundbegriff der atemmechanik. Dieretraktionskraft der lunge, abhangig von der oberflachenspannung in den alveolen. Z Ges Exp Med. 1929;66:373–94.

    Google Scholar 

  2. Gruenwald P. Surface tension as a factor in the resistance of neonatal lungs to aeration. Am J Obstet Gynecol. 1947;53:996–1007.

    CAS  PubMed  Google Scholar 

  3. Mead J, Whittenberger JL, Radford EP. Surface tension as a factor in pulmonary volume-pressure hysteresis. J Appl Physiol. 1957;10:191–6.

    CAS  PubMed  Google Scholar 

  4. Pattle RE. Properties, function, and origin of the alveolar lining layer. Nature. 1955;175:1125–6.

    CAS  PubMed  Google Scholar 

  5. Clements JA. Surface tension of lung extracts. Proc Soc Exp Biol Med. 1957;95:170–2.

    CAS  PubMed  Google Scholar 

  6. Brown ES. Lung area from surface tension effects. Proc Soc Exp Biol Med. 1957;95:168–70.

    CAS  PubMed  Google Scholar 

  7. Pattle RE. Properties, function and origin of the alveolar lining layer. Proc R Soc Lond B Biol Sci. 1958;148:217–40.

    CAS  PubMed  Google Scholar 

  8. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child. 1959;97:517–23.

    CAS  Google Scholar 

  9. Robillard E, Alarie Y, Dagenais-Perusse P, Baril E, Guilbeault A. Microaerosol administration of synthetic b, g-dipalmitoyl-L-a-lecithin in the respiratory distress syndrome: a preliminary report. Can Med Assoc J. 1964;90:55–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  10. Chu J, Clements JA, Cotton EK, et al. The pulmonary hypoperfusion syndrome. Pediatrics. 1965;35:733–42.

    CAS  PubMed  Google Scholar 

  11. Chu J, Clements JA, Cotton EK, Klaus MH, Sweet AY, Tooley WH. Neonatal pulmonary ischemia. Clinical and physiologic studies. Pediatrics. 1967;40:709–82.

    PubMed  Google Scholar 

  12. Notter RH. Lung surfactants: basic science and clinical applications. New York: Marcel Dekker; 2000.

    Google Scholar 

  13. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet. 1980;1:55–9.

    CAS  PubMed  Google Scholar 

  14. Willson DF, Chess PR, Wang Z, Notter RH. Pulmonary surfactant: biology and therapy. In: DA Wheeler WH, Shanley TA, editors. Pediatric critical care medicine: basic science and clinical evidence. London: Springer; 2007. p. 453–66.

    Google Scholar 

  15. Wang Z, Baatz JE, Holm BA, Notter RH. Content-dependent activity of lung surfactant protein B (SP-B) in mixtures with lipids. Am J Physiol. 2002;283:L897–906.

    CAS  Google Scholar 

  16. Wang Z, Gurel O, Baatz JE, Notter RH. Differential activity and lack of synergy of lung surfactant proteins SP-B and SP-C in surface-active interactions with phospholipids. J Lipid Res. 1996;37:1749–60.

    CAS  PubMed  Google Scholar 

  17. Seeger W, Günther A, Thede C. Differential sensitivity to fibrinogen inhibition of SP-C- vs SP-B-based surfactants. Am J Physiol. 1992;261:L286–91.

    Google Scholar 

  18. Notter RH, Wang Z. Pulmonary surfactant: physical chemistry, physiology and replacement. Rev Chem Eng. 1997;13:1–118.

    CAS  Google Scholar 

  19. Notter RH, Wang Z, Egan EA, Holm BA. Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids. 2002;114:21–34.

    CAS  PubMed  Google Scholar 

  20. Whitsett JA, Nogee LM, Weaver TE, Horowitz AD. Human surfactant protein B structure, function, regulation, and genetic disease. Physiol Rev. 1995;75:749–57.

    CAS  PubMed  Google Scholar 

  21. de Mello DE, Nogee LM, Heyman S, et al. Molecular and phenotypic variability in the congenital alveolar proteinosis syndrome associated with inherited surfactant protein B deficiency. J Pediatr. 1994;125:43–50.

    Google Scholar 

  22. Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest. 1994;93:1860–3.

    CAS  PubMed Central  PubMed  Google Scholar 

  23. Nogee LM, Wert SE, Proffit SA, Whitsett JA. Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency. Am J Respir Crit Care Med. 2000;161:973–81.

    CAS  PubMed  Google Scholar 

  24. Hamvas A, Cole FS, deMello DE, et al. Surfactant protein B deficiency: antenatal diagnosis and prospective treatment with surfactant replacement. J Pediatr. 1994;125:356–61.

    CAS  PubMed  Google Scholar 

  25. Hamvas A, Nogee LM, deMello DE, Cole FS. Pathophysiology and treatment of surfactant protein-B deficiency. Biol Neonate. 1995;67 Suppl 1:18–31.

    PubMed  Google Scholar 

  26. Hamvas A, Nogee LM, Mallory GB, et al. Lung transplantation for treatment of infants with surfactant protein B deficiency. J Pediatr. 1997;130:231–9.

    CAS  PubMed  Google Scholar 

  27. Ikegami M, Whitsett JA, Martis PC, Weaver TE. Reversibility of lung inflammation caused by SP-B deficiency. Am J Physiol Lung Cell Mol Physiol. 2005;289:L962–70.

    CAS  PubMed  Google Scholar 

  28. Nogee LM, Dunbar AE, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001;344:573–9.

    CAS  PubMed  Google Scholar 

  29. Crouch E, Wright JR. Surfactant proteins A and D and pulmonary host defense. Annu Rev Physiol. 2001;63:521–54.

    CAS  PubMed  Google Scholar 

  30. Lawson PR, Reid KBM. The roles of surfactant proteins A and D in innate immunity. Immunol Rev. 2000;173:66–78.

    CAS  PubMed  Google Scholar 

  31. Mason RJ, Greene K, Voelker DR. Surfactant protein A and surfactant protein D in health and disease. Am J Physiol. 1998;275:L1–13.

    CAS  PubMed  Google Scholar 

  32. Wright JR. Immunomodulatory functions of surfactant. Physiol Rev. 1997;77:931–62.

    CAS  PubMed  Google Scholar 

  33. LeVine AM, Bruno MD, Huelsman KM, Ross GF, Whitsett JA. Surfactant protein A deficient mice are susceptible to group B streptococcal infection. J Immunol. 1997;158:4336–40.

    CAS  PubMed  Google Scholar 

  34. LeVine AM, Kurak KE, Bruno MD, Stark JM, Whitsett JA, Korfhagen TA. Surfactant protein A-deficient mice are susceptible to Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol. 1998;19:700–8.

    CAS  PubMed  Google Scholar 

  35. Korfhagen TR, Sheftelyevich V, Burhans MS, et al. Surfactant protein D regulates surfactant phospholipid homeostasis in vivo. J Biol Chem. 1998;273:28438–43.

    CAS  PubMed  Google Scholar 

  36. Lim BL, Wang JY, Holmskov U, Hoppe HJ, Reid KB. Expression of the carbohydrate recognition domain of lung surfactant protein D and demonstration of its binding to lipopolysaccharides of gram-negative bacteria. Biochem Biophys Res Commun. 1994;202:1674–80.

    CAS  PubMed  Google Scholar 

  37. Ferguson JS, Voelker DR, McCormack FX, Schlesinger LS. Surfactant protein D binds to Mycobacterium tuberculosis bacilli and liparabinomannan via carbohydrate-lectin interactions resulting in reduced phagocytosis of the bacteria by the macrophages. J Immunol. 1999;163:312–21.

    CAS  PubMed  Google Scholar 

  38. Wright JR. Clearance and recycling of pulmonary surfactant. Am J Physiol. 1990;259:L1–12.

    CAS  PubMed  Google Scholar 

  39. Batenburg JJ. Surfactant phospholipids: synthesis and storage. Am J Physiol. 1992;262:L367–85.

    CAS  PubMed  Google Scholar 

  40. Hawgood S. Surfactant: composition, structure, and metabolism. In: Crystal RG, West JB, Weibel ER, Barnes PJ, editors. The lung: scientific foundations. 2nd ed. Philadelphia: Lippincott-Raven; 1997. p. 557–71.

    Google Scholar 

  41. Hawgood S, Poulain FR. The pulmonary collectins and surfactant metabolism. Annu Rev Physiol. 2001;63:495–519.

    CAS  PubMed  Google Scholar 

  42. van Golde LMG, Casals CC. Metabolism of lipids. In: Crystal RG, West JB, Weibel ER, Barnes PJ, editors. The lung: scientific foundations. 2nd ed. Philadelphia: Lippincott-Raven; 1997. p. 9–18.

    Google Scholar 

  43. Haagsman HP, van Golde LMG. Synthesis and assembly of lung surfactant. Annu Rev Physiol. 1991;53:441–64.

    CAS  PubMed  Google Scholar 

  44. Johansson J, Curstedt T, Robertson B. The proteins of the surfactant system. Eur Respir J. 1994;7:372–91.

    CAS  PubMed  Google Scholar 

  45. Rooney SA, Young SL, Mendelson CR. Molecular and cellular processing of lung surfactant. FASEB J. 1994;8:957–67.

    CAS  PubMed  Google Scholar 

  46. Mendelson CR, Alcorn JL, Gao E. The pulmonary surfactant protein genes and their regulation in fetal lung. Semin Perinatol. 1993;17:223–32.

    CAS  PubMed  Google Scholar 

  47. Oosterlaken-Dijksterhuis MA, van Eijk M, van Buel BLM, van Golde LMG, Haagsman HP. Surfactant protein composition of lamellar bodies isolated from rat lung. Biochem J. 1991;274:115–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  48. O’Reilly MA, Nogee L, Whitsett JA. Requirement of the collagenous domain for carbohydrate processing and secretion of a surfactant protein, SP-A. Biochim Biophys Acta. 1988;969:176–84.

    PubMed  Google Scholar 

  49. Pinto RA, Wright JR, Lesikar D, Benson BJ, Clements JA. Uptake of pulmonary surfactant protein C into adult rat lung lamellar bodies. J Appl Physiol. 1993;74:1005–11.

    CAS  PubMed  Google Scholar 

  50. Walker SR, Williams MC, Benson B. Immunocytochemical localization of the major surfactant proteins in type II cells, Clara cells, and alveolar macrophages of rat lungs. J Histochem Cytochem. 1986;34:1137–48.

    CAS  PubMed  Google Scholar 

  51. Weaver TE, Whitsett JA. Processing of hydrophobic pulmonary surfactant protein B in rat type II cells. Am J Physiol. 1989;257:L100–8.

    CAS  PubMed  Google Scholar 

  52. Vorhout WF, Veenendaal T, Kuroki Y, Ogasawara Y, van Golde LMG, Geuze HJ. Immunocytochemical localization of surfactant protein D (SP-D) in type II cell, Clara cells, and alveolar macrophages of rat lung. J Histochem Cytochem. 1992;40:1589–97.

    Google Scholar 

  53. Crouch E, Rust K, Marienchek W, Parghi D, Chang D, Persson A. Developmental expression of pulmonary surfactant protein D (SP-D). Am J Respir Cell Mol Biol. 1991;5:13–8.

    CAS  PubMed  Google Scholar 

  54. Williams MC. Conversion of lamellar body membranes into tubular myelin in alveoli of fetal rat lungs. J Cell Biol. 1977;72:260–77.

    CAS  PubMed  Google Scholar 

  55. Williams MC. Ultrastructure of tubular myelin and lamellar bodies in fast-frozen rat lung. Exp Lung Res. 1982;4:37–46.

    CAS  PubMed  Google Scholar 

  56. Williams MC, Hawgood S, Hamilton RL. Changes in lipid structure produced by surfactant proteins SP-A, SP-B, and SP-C. Am J Respir Cell Mol Biol. 1991;5:41–50.

    CAS  PubMed  Google Scholar 

  57. Suzuki Y, Fujita Y, Kogishi K. Reconstitution of tubular myelin from synthetic lipids and proteins associated with pig lung surfactant. Am Rev Respir Dis. 1989;140:75–81.

    CAS  PubMed  Google Scholar 

  58. Wright JR, Clements JA. Metabolism and turnover of lung surfactant. Am Rev Respir Dis. 1987;135:426–44.

    Google Scholar 

  59. Jobe AH, Ikegami M. Surfactant metabolism. Clin Perinatol. 1993;20:683–96.

    CAS  PubMed  Google Scholar 

  60. Williams MC. Uptake of lectins by alveolar type II cells: subsequent deposition into lamellar bodies. Proc Natl Acad Sci U S A. 1984;81:6383–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  61. Wright JR, Wager RE, Hamilton RL, Huang M, Clements JA. Uptake of lung surfactant subfractions into lamellar bodies of adult rabbit lungs. J Appl Physiol. 1986;60:817–25.

    CAS  PubMed  Google Scholar 

  62. Wright JR, Wager RE, Hawgood S, Dobbs LG, Clements JA. Surfactant apoprotein Mr = 26,000-36,000 enhances uptake of liposomes by type II cells. J Biol Chem. 1987;262:2888–94.

    CAS  PubMed  Google Scholar 

  63. Young SL, Wright JR, Clements JA. Cellular uptake and processing of surfactant lipids and apoprotein SP-A by rat lung. J Appl Physiol. 1989;66:1336–42.

    CAS  PubMed  Google Scholar 

  64. Claypool WD, Wang DL, Chandler A, Fisher AB. An ethanol/ether soluble apoprotein from rat lung surfactant augments liposomes uptake by isolated granular pneumocytes. J Clin Invest. 1984;74:677–84.

    CAS  PubMed Central  PubMed  Google Scholar 

  65. Rice WR, Sarin VK, Fox JL, Baatz J, Wert S, Whitsett JA. Surfactant peptides stimulate uptake of phosphatidylcholine by isolated cells. Biochim Biophys Acta. 1989;1006:237–45.

    CAS  PubMed  Google Scholar 

  66. Notter RH, Finkelstein JN, Holm BA. Lung injury: mechanisms, pathophysiology and therapy. Boca Raton: Taylor Francis Group; 2005.

    Google Scholar 

  67. Raghavendran K, Pryhuber GS, Chess PR, Davidson BA, Knight PR, Notter RH. Pharmacotherapy of acute lung injury and acute respiratory distress syndrome. Curr Med Chem. 2008;15:1911–24.

    CAS  PubMed Central  PubMed  Google Scholar 

  68. Raghavendran KR, Willson D, Notter RH. Surfactant therapy of acute lung injury and acute respiratory distress syndrome. Crit Care Clin. 2011;27:525–59.

    CAS  PubMed Central  PubMed  Google Scholar 

  69. Knight PR, Rotta AT. Acute lung injury: etiologies and basic features. In: Notter RH, Finkelstein JN, Holm BA, editors. Lung injury: mechanisms, pathophysiology, and therapy. Boca Raton: Taylor & Francis Group; 2005. p. 67–110.

    Google Scholar 

  70. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353:1685–93.

    CAS  PubMed  Google Scholar 

  71. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967;2:319–23.

    CAS  PubMed  Google Scholar 

  72. Petty TL, Ashbaugh DG. The adult respiratory distress syndrome. Clinical features, factors influencing prognosis and principles of management. Chest. 1971;60:233–9.

    CAS  PubMed  Google Scholar 

  73. Petty T, Reiss O, Paul G, Silvers G, Elkins N. Characteristics of pulmonary surfactant in adult respiratory distress syndrome associated with trauma and shock. Am Rev Respir Dis. 1977;115:531–6.

    CAS  PubMed  Google Scholar 

  74. Wang Z, Holm BA, Matalon S, Notter RH. Surfactant activity and dysfunction in lung injury. In: Notter RH, Finkelstein JN, Holm BA, editors. Lung injury: mechanisms, pathophysiology, and therapy. Boca Raton: Taylor Francis Group; 2005. p. 297–352.

    Google Scholar 

  75. Holm BA, Enhorning G, Notter RH. A biophysical mechanism by which plasma proteins inhibit lung surfactant activity. Chem Phys Lipids. 1988;49:49–55.

    CAS  PubMed  Google Scholar 

  76. Holm BA, Wang Z, Notter RH. Multiple mechanisms of lung surfactant inhibition. Pediatr Res. 1999;46:85–93.

    CAS  PubMed  Google Scholar 

  77. Holm BA, Notter RH. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J Appl Physiol. 1987;63:1434–42.

    CAS  PubMed  Google Scholar 

  78. Wang Z, Notter RH. Additivity of protein and non-protein inhibitors of lung surfactant activity. Am J Respir Crit Care Med. 1998;158:28–35.

    CAS  PubMed  Google Scholar 

  79. Hall SB, Lu ZR, Venkitaraman AR, Hyde RW, Notter RH. Inhibition of pulmonary surfactant by oleic acid: mechanisms and characteristics. J Appl Physiol. 1992;72:1708–16.

    CAS  PubMed  Google Scholar 

  80. Pison U, Tam EK, Caughey GH, Hawgood S. Proteolytic inactivation of dog lung surfactant-associated proteins by neutrophil elastase. Biochim Biophys Acta. 1989;992:251–7.

    CAS  PubMed  Google Scholar 

  81. Enhorning G, Shumel B, Keicher L, Sokolowski J, Holm BA. Phospholipases introduced into the hypophase affect the surfactant film outlining a bubble. J Appl Physiol. 1992;73:941–5.

    CAS  PubMed  Google Scholar 

  82. Wang Z, Schwan AL, Lairson LL, et al. Surface activity of a synthetic lung surfactant containing a phospholipase-resistant phosphonolipid analog of dipalmitoyl phosphatidylcholine. Am J Physiol. 2003;285:L550–9.

    CAS  Google Scholar 

  83. Magoon MW, Wright JR, Baritussio A, et al. Subfractionation of lung surfactant: implications for metabolism and surface activity. Biochim Biophys Acta. 1983;750:18–31.

    CAS  PubMed  Google Scholar 

  84. Wright JR, Benson BJ, Williams MC, Goerke J, Clements JA. Protein composition of rabbit alveolar surfactant subfractions. Biochim Biophys Acta. 1984;791:320–32.

    CAS  PubMed  Google Scholar 

  85. Gross NJ, Narine KR. Surfactant subtypes in mice: characterization and quantitation. J Appl Physiol. 1989;66:342–9.

    CAS  PubMed  Google Scholar 

  86. Hall SB, Hyde RW, Notter RH. Changes in subphase surfactant aggregates in rabbits injured by free fatty acid. Am J Respir Crit Care Med. 1994;149:1099–106.

    CAS  PubMed  Google Scholar 

  87. Putz G, Goerke J, Clements JA. Surface activity of rabbit pulmonary surfactant subfractions at different concentrations in a captive bubble. J Appl Physiol. 1994;77:597–605.

    CAS  PubMed  Google Scholar 

  88. Putman E, Creuwels LAJM, Van Golde LMG, Haagsman HP. Surface properties, morphology and protein composition of pulmonary surfactant subtypes. Biochem J. 1996;320:599–605.

    CAS  PubMed Central  PubMed  Google Scholar 

  89. Veldhuizen RAW, Hearn SA, Lewis JF, Possmayer F. Surface-area cycling of different surfactant preparations: SP-A and SP-B are essential for large aggregate integrity. Biochem J. 1994;300:519–24.

    CAS  PubMed Central  PubMed  Google Scholar 

  90. Gross NJ. Extracellular metabolism of pulmonary surfactant: the role of a new serine protease. Annu Rev Physiol. 1995;57:135–50.

    CAS  PubMed  Google Scholar 

  91. Günther A, Siebert C, Schmidt R, et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med. 1996;153:176–84.

    PubMed  Google Scholar 

  92. Veldhuizen RAW, McCaig LA, Akino T, Lewis JF. Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome. Am J Respir Crit Care Med. 1995;152: 1867–71.

    CAS  PubMed  Google Scholar 

  93. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J. 1999;13:1455–76.

    CAS  PubMed  Google Scholar 

  94. Pison U, Seeger W, Buchhorn R, et al. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis. 1989;140:1033–9.

    CAS  PubMed  Google Scholar 

  95. Lewis JF, Ikegami M, Jobe AH. Altered surfactant function and metabolism in rabbits with acute lung injury. J Appl Physiol. 1990;69:2303–10.

    CAS  PubMed  Google Scholar 

  96. Putman E, Boere AJ, van Bree L, van Golde LMG, Haagsman HP. Pulmonary surfactant subtype metabolism is altered after short-term ozone exposure. Toxicol Appl Pharmacol. 1995;134:132–8.

    CAS  PubMed  Google Scholar 

  97. Atochina EN, Beers MF, Scanlon ST, Preston AM, Beck JM. P. carinii induces selective alterations in component expression and biophysical activity of lung surfactant. Am J Physiol. 2000;278:L599–609.

    CAS  Google Scholar 

  98. Davidson BA, Knight PR, Wang Z, et al. Surfactant alterations in acute inflammatory lung injury from aspiration of acid and gastric particulates. Am J Physiol Lung Cell Mol Physiol. 2005;288:L699–708.

    CAS  PubMed  Google Scholar 

  99. Seeger W, Pison U, Buchhorn R, Obestacke U, Joka T. Surfactant abnormalities and adult respiratory failure. Lung. 1990;168(Suppl): 891–902.

    PubMed  Google Scholar 

  100. Gregory TJ, Longmore WJ, Moxley MA, et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest. 1991;88:1976–81.

    CAS  PubMed Central  PubMed  Google Scholar 

  101. Pison U, Obertacke U, Brand M, et al. Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure. J Trauma. 1990;30:19–26.

    CAS  PubMed  Google Scholar 

  102. Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L. Evidence of lung surfactant abnormality in respiratory failure. J Clin Invest. 1982;70:673–83.

    CAS  PubMed Central  PubMed  Google Scholar 

  103. Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med. 1996;334:1417–21.

    CAS  PubMed  Google Scholar 

  104. Chess P, Finkelstein JN, Holm BA, Notter RH. Surfactant replacement therapy in lung injury. In: Notter RH, Finkelstein JN, Holm BA, editors. Lung injury: mechanisms, pathophysiology, and therapy. Boca Raton: Taylor Francis Group; 2005. p. 617–63.

    Google Scholar 

  105. Soll RF. Appropriate surfactant usage in 1996. Eur J Pediatr. 1996;155:S8–13.

    PubMed  Google Scholar 

  106. Soll RF. Surfactant therapy in the USA: trials and current routines. Biol Neonate. 1997;71:1–7.

    PubMed  Google Scholar 

  107. Halliday HL. Controversies – synthetic or natural surfactant – the case for natural surfactant. J Perinat Med. 1996;24(5):417–26.

    CAS  PubMed  Google Scholar 

  108. Jobe AH. Pulmonary surfactant therapy. N Engl J Med. 1993;328:861–8.

    CAS  PubMed  Google Scholar 

  109. Sweet DG, Halliday HL. The use of surfactants in 2009. Arch Dis Child Educ Pract Ed. 2009;94:78–83.

    CAS  PubMed  Google Scholar 

  110. Hall SB, Venkitaraman AR, Whitsett JA, Holm BA, Notter RH. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants. Am Rev Respir Dis. 1992;145:24–30.

    CAS  PubMed  Google Scholar 

  111. Seeger W, Grube C, Günther A, Schmidt R. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J. 1993;6:971–7.

    CAS  PubMed  Google Scholar 

  112. Hudak ML, Farrell EE, Rosenberg AA, et al. A multicenter randomized masked comparison of natural vs synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr. 1996;128:396–406.

    CAS  PubMed  Google Scholar 

  113. Hudak ML, Martin DJ, Egan EA, et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics. 1997;100:39–50.

    CAS  PubMed  Google Scholar 

  114. Vermont-Oxford Neonatal Network. A multicenter randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics. 1996;97:1–6.

    Google Scholar 

  115. Horbar JD, Wright LL, Soll RF, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr. 1993;123:757–66.

    CAS  PubMed  Google Scholar 

  116. Halliday HL. Overview of clinical trials comparing natural and synthetic surfactants. Biol Neonate. 1995;67(Suppl):32–47.

    PubMed  Google Scholar 

  117. Wiseman LR, Bryson HM. Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome. Drugs. 1994;48:386–403.

    CAS  PubMed  Google Scholar 

  118. Mizuno K, Ikegami M, Chen C-M, Ueda T, Jobe AH. Surfactant protein-B supplementation improves in vivo function of a modified natural surfactant. Pediatr Res. 1995;37:271–6.

    CAS  PubMed  Google Scholar 

  119. Yu SH, Possmayer F. Comparative studies on the biophysical activities of the low-molecular-weight hydrophobic proteins purified from bovine pulmonary surfactant. Biochim Biophys Acta. 1988;961:337–50.

    CAS  PubMed  Google Scholar 

  120. Oosterlaken-Dijksterhuis MA, van Eijk M, van Golde LMG, Haagsman HP. Lipid mixing is mediated by the hydrophobic surfactant protein SP-B but not by SP-C. Biochim Biophys Acta. 1992;1110:45–50.

    CAS  PubMed  Google Scholar 

  121. Walther FJ, Hernandez-Juviel J, Bruni R, Waring A. Spiking Survanta with synthetic surfactant peptides improves oxygenation in surfactant-deficient rats. Am J Respir Crit Care Med. 1997;156:855–61.

    CAS  PubMed  Google Scholar 

  122. Notter RH, Schwan AL, Wang Z, Waring AJ. Novel phospholipase-resistant lipid/peptide synthetic lung surfactants. Mini Rev Med Chem. 2007;7:932–44.

    CAS  PubMed  Google Scholar 

  123. Mingarro I, Lukovic D, Vilar M, Pérez-Gil J. Synthetic pulmonary surfactant preparations: new developments and future trends. Curr Med Chem. 2008;15:303–403.

    Google Scholar 

  124. Walther FJ, Waring AJ, Sherman MA, Zasadzinski J, Gordon LM. Hydrophobic surfactant proteins and their analogues. Neonatology. 2007;91:303–10.

    CAS  PubMed  Google Scholar 

  125. Curstedt T, Johansson J. New synthetic surfactant – how and when? Biol Neonate. 2006;89:336–9.

    PubMed  Google Scholar 

  126. Walther FJ, Waring AJ, Hernandez-Juviel JM, et al. Dynamic surface activity of a fully-synthetic phospholipase-resistant lipid/peptide lung surfactant. PLoS One. 2007;2(10):e1039. doi:10.1371/journal.pone.0001039.

    PubMed Central  PubMed  Google Scholar 

  127. Waring AJ, Walther FJ, Gordon LM, et al. The role of charged amphipathic helices in the structure and function of surfactant protein B (SP-B). J Pept Res. 2005;66:364–74.

    CAS  PubMed  Google Scholar 

  128. Walther FJ, Waring AJ, Hernandez-Juviel JM, et al. Critical structural and functional roles for the N-terminal insertion sequence in surfactant protein B analogs. PLoS One. 2010;5:e8672. doi:10.1371/journal.pone.0008672.

    PubMed Central  PubMed  Google Scholar 

  129. Turcotte JG, Sacco AM, Steim JM, Tabak SA, Notter RH. Chemical synthesis and surface properties of an analog of the pulmonary surfactant dipalmitoyl phosphatidylcholine analog. Biochim Biophys Acta. 1977;488:235–48.

    CAS  PubMed  Google Scholar 

  130. Turcotte JG, Lin WH, Pivarnik PE, et al. Chemical synthesis and surface activity of lung surfactant phospholipid analogs. II. Racemic N-substituted diether phosphonolipids. Biochim Biophys Acta. 1991;1084:1–12.

    CAS  PubMed  Google Scholar 

  131. Wang Z, Chang Y, Schwan AL, Notter RH. Activity and inhibition resistance of a phospholipase-resistant synthetic exogenous surfactant in excised rat lungs. Am J Respir Cell Mol Biol. 2007;37:387–94.

    CAS  PubMed Central  PubMed  Google Scholar 

  132. Notter RH, Wang Z, Wang Z, Davy J, Schwan AL. Synthesis and surface activity of diether-linked phosphoglycerols: potential applications for exogenous lung surfactants. Bioorg Med Chem Lett. 2007;17:113–7.

    CAS  PubMed  Google Scholar 

  133. Chang Y, Wang Z, Schwan AL, et al. Surface properties of sulfur- and ether-linked phosphonolipids with and without purified hydrophobic lung surfactant proteins. Chem Phys Lipids. 2005;137:77–93.

    CAS  PubMed  Google Scholar 

  134. Schwan AL, Singh SP, Davy JA, et al. Synthesis and activity of a novel diether phosphonoglycerol in phospholipase-resistant synthetic lipid: peptide lung surfactants. Med Chem Commun. 2011;2:1167–73.

    CAS  Google Scholar 

  135. Kim DK, Fukuda T, Thompson BT, Cockrill B, Hales C, Bonventre JV. Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome. Am J Physiol. 1995;269:L109–18.

    CAS  PubMed  Google Scholar 

  136. Touqui L, Arbibe L. A role for phospholipase A2 in ARDS pathogenesis. Mol Med Today. 1999;5:244–9.

    CAS  PubMed  Google Scholar 

  137. Vadas P. Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock. J Lab Clin Med. 1984;104:873–81.

    CAS  PubMed  Google Scholar 

  138. Vadas P, Pruzanski W. Biology of disease: role of secretory phospholipases A2 in the pathobiology of disease. Lab Invest. 1986;55:391–404.

    CAS  PubMed  Google Scholar 

  139. Ackerman SJ, Kwatia MA, Doyle CB, Enhorning G. Hydrolysis of surfactant phospholipids catalyzed by phospholipase A2 and eosinophil lysophospholipases causes surfactant dysfunction: a mechanism for small airway closure in asthma. Chest. 2003;123:255S.

    Google Scholar 

  140. Attalah HL, Wu Y, Alaoui-El-Azher M, et al. Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury. Eur Respir J. 2003;21:1040–5.

    CAS  PubMed  Google Scholar 

  141. Nakos G, Kitsiouli E, Hatzidaki E, Koulouras V, Touqui L, Lekka ME. Phospholipases A2 and platelet-activating–factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med. 2003;33:772–9.

    Google Scholar 

  142. Kobayashi T, Ganzuka M, Taniguchi J, Nitta K, Murakami S. Lung lavage and surfactant replacement for hydrochloric acid aspiration in rabbits. Acta Anaesthesiol Scand. 1990;34:216–21.

    CAS  PubMed  Google Scholar 

  143. Zucker A, Holm BA, Wood LDH, Crawford G, Ridge K, Sznajder IA. Exogenous surfactant with PEEP reduces pulmonary edema and improves lung function in canine aspiration pneumonitis. J Appl Physiol. 1992;73:679–86.

    CAS  PubMed  Google Scholar 

  144. Schlag G, Strohmaier W. Experimental aspiration trauma: comparison of steroid treatment versus exogenous natural surfactant. Exp Lung Res. 1993;19:397–405.

    PubMed  Google Scholar 

  145. Al-Mateen KB, Dailey K, Grimes MM, Gutcher GR. Improved oxygenation with exogenous surfactant administration in experimental meconium aspiration syndrome. Pediatr Pulmonol. 1994;17:75–80.

    CAS  PubMed  Google Scholar 

  146. Sun B, Curstedt T, Robertson B. Exogenous surfactant improves ventilation efficiency and alveolar expansion in rats with meconium aspiration. Am J Respir Crit Care Med. 1996;154:764–70.

    CAS  PubMed  Google Scholar 

  147. Cochrane CG, Revak SD, Merritt TA, et al. Bronchoalveolar lavage with KL4-surfactant in models of meconium aspiration syndrome. Pediatr Res. 1998;44:705–15.

    CAS  PubMed  Google Scholar 

  148. Sun B, Curstedt T, Song GW, Robertson B. Surfactant improves lung function and morphology in newborn rabbits with meconium aspiration. Biol Neonate. 1993;63:96–104.

    CAS  PubMed  Google Scholar 

  149. Lachmann B, Hallman M, Bergman K-C. Respiratory failure following anti-lung serum: study on mechanisms associated with surfactant system damage. Exp Lung Res. 1987;12:163–80.

    CAS  PubMed  Google Scholar 

  150. Nieman G, Gatto L, Paskanik A, Yang B, Fluck R, Picone A. Surfactant replacement in the treatment of sepsis-induced adult respiratory distress syndrome in pigs. Crit Care Med. 1996;24:1025–33.

    CAS  PubMed  Google Scholar 

  151. Lutz C, Carney D, Finck C, et al. Aerosolized surfactant improves pulmonary function in endotoxin-induced lung injury. Am J Respir Crit Care Med. 1998;158:840–5.

    CAS  PubMed  Google Scholar 

  152. Lutz CJ, Picone A, Gatto LA, Paskanik A, Landas S, Nieman G. Exogenous surfactant and positive end-expiratory pressure in the treatment of endotoxin-induced lung injury. Crit Care Med. 1998;26:1379–89.

    CAS  PubMed  Google Scholar 

  153. Tashiro K, Li W-Z, Yamada K, Matsumoto Y, Kobayashi T. Surfactant replacement reverses respiratory failure induced by intratracheal endotoxin in rats. Crit Care Med. 1995;23:149–56.

    CAS  PubMed  Google Scholar 

  154. Eijking EP, van Daal GJ, Tenbrinck R, et al. Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats. Intensive Care Med. 1990;17:475–8.

    Google Scholar 

  155. Sherman MP, Campbell LA, Merritt TA, et al. Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits. J Pediatr. 1994;125:939–47.

    CAS  PubMed  Google Scholar 

  156. Berry D, Ikegami M, Jobe A. Respiratory distress and surfactant inhibition following vagotomy in rabbits. J Appl Physiol. 1986;61:1741–8.

    CAS  PubMed  Google Scholar 

  157. Matalon S, Holm BA, Notter RH. Mitigation of pulmonary hyperoxic injury by administration of exogenous surfactant. J Appl Physiol. 1987;62:756–61.

    CAS  PubMed  Google Scholar 

  158. Loewen GM, Holm BA, Milanowski L, Wild LM, Notter RH, Matalon S. Alveolar hyperoxic injury in rabbits receiving exogenous surfactant. J Appl Physiol. 1989;66:1987–92.

    Google Scholar 

  159. Engstrom PC, Holm BA, Matalon S. Surfactant replacement attenuates the increase in alveolar permeability in hyperoxia. J Appl Physiol. 1989;67:688–93.

    CAS  PubMed  Google Scholar 

  160. Matalon S, Holm BA, Loewen GM, Baker RR, Notter RH. Sublethal hyperoxic injury to the alveolar epithelium and the pulmonary surfactant system. Exp Lung Res. 1988;14:1021–33.

    CAS  PubMed  Google Scholar 

  161. Novotny WE, Hudak BB, Matalon S, Holm BA. Hyperoxic lung injury reduces exogenous surfactant clearance in vitro. Am J Respir Crit Care Med. 1995;151:1843–7.

    CAS  PubMed  Google Scholar 

  162. Lachmann B, Fujiwara T, Chida S, et al. Surfactant replacement therapy in experimental adult respiratory distress syndrome (ARDS). In: Cosmi EV, Scarpelli EM, editors. Pulmonary surfactant system. Amsterdam: Elsevier; 1983. p. 221–35.

    Google Scholar 

  163. Kobayashi T, Kataoka H, Ueda T, Murakami S, Takada Y, Kobuko M. Effect of surfactant supplementation and end expiratory pressure in lung-lavaged rabbits. J Appl Physiol. 1984;57:995–1001.

    CAS  PubMed  Google Scholar 

  164. Berggren P, Lachmann B, Curstedt T, Grossmann G, Robertson B. Gas exchange and lung morphology after surfactant replacement in experimental adult respiratory distress induced by repeated lung lavage. Acta Anaesthesiol Scand. 1986;30:321–8.

    CAS  PubMed  Google Scholar 

  165. Lewis JF, Goffin J, Yue P, McCaig LA, Bjarneson D, Veldhuizen RAW. Evaluation of exogenous surfactant treatment strategies in an adult model of acute lung injury. J Appl Physiol. 1996;80:1156–64.

    CAS  PubMed  Google Scholar 

  166. Walther F, Hernandez-Juviel J, Bruni R, Waring AJ. Protein composition of synthetic surfactant affects gas exchange in surfactant-deficient rats. Pediatr Res. 1998;43:666–73.

    CAS  PubMed  Google Scholar 

  167. Harris JD, Jackson F, Moxley MA, Longmore WJ. Effect of exogenous surfactant instillation on experimental acute lung injury. J Appl Physiol. 1989;66:1846–51.

    CAS  PubMed  Google Scholar 

  168. Lewis JF, Ikegami M, Jobe AH. Metabolism of exogenously administered surfactant in the acutely injured lungs of adult rabbits. Am Rev Respir Dis. 1992;145:19–23.

    CAS  PubMed  Google Scholar 

  169. Lewis J, Ikegami M, Higuchi R, Jobe A, Absolom D. Nebulized vs. instilled exogenous surfactant in an adult lung injury model. J Appl Physiol. 1991;71:1270–6.

    CAS  PubMed  Google Scholar 

  170. Raghavendran K, Davidson BA, Knight PR, et al. Surfactant dysfunction in lung contusion with and without superimposed gastric aspiration in a rat model. Shock. 2008;30:508–17.

    CAS  PubMed Central  PubMed  Google Scholar 

  171. van Daal GJ, So KL, Gommers D, et al. Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia. Anesth Analg. 1991;72:589–95.

    PubMed  Google Scholar 

  172. van Daal GJ, Bos JAH, Eijking EP, Gommers D, Hannappel E, Lachmann B. Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice. Am Rev Respir Dis. 1992;145:859–63.

    PubMed  Google Scholar 

  173. Gunther A, Schmidt R, Harodt J, et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J. 2002;10:797–804.

    Google Scholar 

  174. Walmrath D, Gunther A, Ghofrani HA, et al. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med. 1996;154:57–62.

    CAS  PubMed  Google Scholar 

  175. Spragg RG, Gilliard N, Richman P, et al. Acute effects of a single dose of porcine surfactant on patients with acute respiratory distress syndrome. Chest. 1994;105:95–202.

    Google Scholar 

  176. Spragg RG, Lewis JF, Wurst W, et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med. 2003;167:1562–6.

    PubMed  Google Scholar 

  177. Amital A, Shitrit D, Raviv Y, et al. The use of surfactant in lung transplantation. Transplantation. 2008;86:1554–9.

    CAS  PubMed  Google Scholar 

  178. Wiswell TE, Smith RM, Katz LB, et al. Bronchopulmonary segmental lavage with surfaxin (KL(4) – surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med. 1999;160:1188–95.

    CAS  PubMed  Google Scholar 

  179. Willson DF, Jiao JH, Bauman LA, et al. Calf lung surfactant extract in acute hypoxemic respiratory failure in children. Crit Care Med. 1996;24:1316–22.

    CAS  PubMed  Google Scholar 

  180. Willson DF, Bauman LA, Zaritsky A, et al. Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Crit Care Med. 1999;27:188–95.

    CAS  PubMed  Google Scholar 

  181. Willson DF, Thomas NJ, Markovitz BP, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA. 2005;293:470–6.

    CAS  PubMed  Google Scholar 

  182. Lopez-Herce J, de Lucas N, Carrillo A, Bustinza A, Moral R. Surfactant treatment for acute respiratory distress syndrome. Arch Dis Child. 1999;80:248–52.

    CAS  PubMed Central  PubMed  Google Scholar 

  183. Hermon MM, Golej J, Burda H, et al. Surfactant therapy in infants and children: three years experience in a pediatric intensive care unit. Shock. 2002;17:247–51.

    PubMed  Google Scholar 

  184. Herting E, Moller O, Schiffman JH, Robertson B. Surfactant improves oxygenation in infants and children with pneumonia and acute respiratory distress syndrome. Acta Paediatr. 2002;91:1174–8.

    CAS  PubMed  Google Scholar 

  185. Moller JC, Schaible T, Roll C, et al. Treatment with bovine surfactant in severe acute respiratory distress syndrome in children: a randomized multicenter study. Intensive Care Med. 2003;29:437–46.

    PubMed  Google Scholar 

  186. Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics. 1991;87:101–7.

    CAS  PubMed  Google Scholar 

  187. Lotze A, Knight GR, Martin GR, et al. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J Pediatr. 1993;122:261–8.

    CAS  PubMed  Google Scholar 

  188. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. J Pediatr. 1998;132:40–7.

    CAS  PubMed  Google Scholar 

  189. Khammash H, Perlman M, Wojtulewicz J, Dunn M. Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics. 1993;92:135–9.

    CAS  PubMed  Google Scholar 

  190. Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics. 1996;97:48–52.

    CAS  PubMed  Google Scholar 

  191. Luchetti M, Casiraghi G, Valsecchi R, Galassini E, Marraro G. Porcine-derived surfactant treatment of severe bronchiolitis. Acta Anaesthesiol Scand. 1998;42:805–10.

    CAS  PubMed  Google Scholar 

  192. Luchetti M, Ferrero F, Gallini C, et al. Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Pediatr Crit Care Med. 2002;3:261–8.

    PubMed  Google Scholar 

  193. Willson D, Notter RH. The future of exogenous surfactant therapy. Respir Care. 2011;56:1369–86.

    PubMed  Google Scholar 

  194. Clark DA, Nieman GF, Thompson JE, Paskanik AM, Rokhar JE, Bredenberg CE. Surfactant displacement by meconium free fatty acids: an alternative explanation for atelectasis in meconium aspiration syndrome. J Pediatr. 1987;110:765–70.

    CAS  PubMed  Google Scholar 

  195. Moses D, Holm BA, Spitale P, Liu M, Enhorning G. Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol. 1991;164:477–81.

    CAS  PubMed  Google Scholar 

  196. Ivascu FA, Hirschl RB. New approaches to managing congenital diaphragmatic hernia. Semin Perinatol. 2004;28:185–98.

    PubMed  Google Scholar 

  197. Van Meurs K, The Congenital Diaphragmatic Hernia Study Group. Is surfactant therapy beneficial in the treatment of the term newborn infants with congenital diaphragmatic hernia? J Pediatr. 2004;145:312–6.

    PubMed  Google Scholar 

  198. Gregory TJ, Steinberg KP, Spragg R, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1997;155:109–31.

    Google Scholar 

  199. Spragg RG, Taut FJ, Lewis JF, et al. Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. Am J Respir Crit Care Med. 2011;183(8):1055–61.

    CAS  PubMed  Google Scholar 

  200. Thomas NJ, Guardia C, Moya FR, et al. A pilot, randomized, controlled clinical trial of lucinactant, a peptide-containing synthetic surfactant, in infants with acute hypoxemic respiratory failure. Pediatr Crit Care Med. 2012;13(6):646–53.

    PubMed  Google Scholar 

  201. Davis JM, Richter SE, Kendig JW, Notter RH. High frequency jet ventilation and surfactant treatment of newborns in severe respiratory failure. Pediatr Pulmonol. 1992;13:108–12.

    CAS  PubMed  Google Scholar 

  202. Davis JM, Notter RH. Lung surfactant replacement for neonatal pathology other than primary respiratory distress syndrome. In: Boynton B, Carlo W, Jobe A, editors. New therapies for neonatal respiratory failure: a physiologic approach. Cambridge: Cambridge University Press; 1994. p. 81–92.

    Google Scholar 

  203. Leach CL, Greenspan JS, Rubenstein SD, et al. Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. N Engl J Med. 1996;335:761–7.

    CAS  PubMed  Google Scholar 

  204. Leach CL, Holm BA, Morin FC, et al. Partial liquid ventilation in premature lambs with respiratory distress syndrome: efficacy and compatibility with exogenous surfactant. J Pediatr. 1995;126:412–20.

    CAS  PubMed  Google Scholar 

  205. Chappell SE, Wolfson MR, Shaffer TH. A comparison of surfactant delivery with conventional mechanical ventilation and partial liquid ventilation in meconium aspiration injury. Respir Med. 2001;95:612–7.

    CAS  PubMed  Google Scholar 

  206. King DM, Wang Z, Kendig JW, Palmer HJ, Holm BA, Notter RH. Concentration-dependent, temperature-dependent non-Newtonian viscosity of lung surfactant dispersions. Chem Phys Lipids. 2001;112:11–9.

    CAS  PubMed  Google Scholar 

  207. King DM, Wang Z, Palmer HJ, Holm BA, Notter RH. Bulk shear viscosities of endogenous and exogenous lung surfactants. Am J Physiol. 2002;282:L277–84.

    CAS  Google Scholar 

  208. Notter RH, Apostolakos M, Holm BA, et al. Surfactant therapy and its potential use with other agents in term infants, children and adults with acute lung injury. Perspect Neonatol. 2000;1(4):4–20.

    Google Scholar 

  209. Pryhuber GS, D’Angio CT, Finkelstein JN, Notter RH. Combination therapies for lung injury. In: Notter RH, Finkelstein JN, Holm BA, editors. Lung injury: mechanisms, pathophysiology, and therapy. Boca Raton: Taylor Francis Group; 2005. p. 779–838.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Penn State CHILD Research, Division of Pediatric Critical Care Medicine, Penn State Children’s Hospital, Pennsylvania State University College of Medicine, 500 University Drive, MC H085, Room H7513, Hershey, PA, 17033, USA

    Neal J. Thomas MD, MSc

  2. Department of Pediatrics, Penn State Hershey Children’s Hospital, 500 University Drive, Hershey, PA, 17033, USA

    Robert F. Tamburro Jr. MD, MSc

  3. Department of Pediatrics, Medical College of Virginia, Richmond, VA, USA

    Douglas F. Willson MD

  4. Department of Pediatrics, University of Rochester, Rochester, NY, USA

    Robert H. Notter MD

Authors
  1. Neal J. Thomas MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert F. Tamburro Jr. MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas F. Willson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert H. Notter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neal J. Thomas MD, MSc .

Editor information

Editors and Affiliations

  1. Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

    Derek S. Wheeler

  2. Div. of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

    Hector R. Wong

  3. Pediatric Critical Care Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA

    Thomas P. Shanley

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Thomas, N.J., Tamburro, R.F., Willson, D.F., Notter, R.H. (2014). Surfactant Therapy. In: Wheeler, D., Wong, H., Shanley, T. (eds) Pediatric Critical Care Medicine. Springer, London. https://doi.org/10.1007/978-1-4471-6356-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-6356-5_11

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-6355-8

  • Online ISBN: 978-1-4471-6356-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation